Publications by authors named "Caroline Dartigeas"

The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative analysis on genetic abnormalities identified through cytogenetics and targeted next-generation sequencing in 536 CLL patients receiving first-line chemo(immuno)therapies (CIT) as part of two prospective trials. We evaluated the prognostic implications of the main abnormalities, with specific attention to their relative impact according to IGHV status.

View Article and Find Full Text PDF
Article Synopsis
  • The FIRE observational study assessed the effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, with a maximum follow-up of five years post-treatment initiation.
  • The study included 388 patients and found median progression-free survival (PFS) of approximately 53 months for both retrospective and prospective patients, with no significant difference in PFS for those with or without dose reductions.
  • The most common adverse events were infections, with a notable percentage of patients experiencing treatment-emergent adverse events leading to death, though overall effectiveness and safety outcomes aligned with previous studies.
View Article and Find Full Text PDF
Article Synopsis
  • - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
  • - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
  • - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
View Article and Find Full Text PDF

Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19), the efficacy and safety of parsaclisib was evaluated in patients with R/R mantle cell lymphoma (MCL).

Methods: Patients ≥18 years old with pathologically confirmed R/R MCL and prior treatment with 1-3 systemic therapies, with (cohort 1) or without (cohort 2) previous Bruton kinase inhibitor (BTKi) treatment, received oral parsaclisib 20 mg once-daily (QD) for 8 weeks, then either parsaclisib 20 mg once-weekly (weekly dosing group [WG]) or parsaclisib 2.

View Article and Find Full Text PDF

In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07 trial evaluated a fixed-duration (15-month) immunochemotherapy approach in which after obinutuzumab-ibrutinib induction for 9 months, patients (n = 10) in complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) <0.01% continued only ibrutinib 420 mg/day for 6 additional months (I arm), whereas the majority (n = 115) received up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside the ibrutinib (I-FCG arm).

View Article and Find Full Text PDF
Article Synopsis
  • Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL) into an aggressive form of lymphoma, primarily diffuse large B-cell lymphoma (DLBCL).
  • Researchers analyzed 58 primary RS samples using DNA methylation and transcriptome profiling, leading to the identification of epigenetic patterns and a method to assess CLL-RS clonal relationships without the original CLL tumor DNA.
  • The study developed classifiers based on DNA and transcriptomic data, revealing a poor-prognosis subset of DLBCL that shares similarities with RS, highlighting the potential to improve prognosis assessment and treatment strategies for affected patients.
View Article and Find Full Text PDF

Waldenström's disease is a B-cell neoplasm characterized by the accumulation of lymphoplasmacytic cells (LPCs) in the bone marrow, and more rarely in the lymph nodes and the spleen, which produce a monoclonal immunoglobulin M (IgM) protein. The diagnosis requires the identification of LPCs in the bone marrow, using specific markers in flow cytometry. The MYD88L265P mutation is found in 95% of cases and the CXCR4 mutation in 30-40% of cases.

View Article and Find Full Text PDF
Article Synopsis
  • * The median follow-up times for CLL/SLL and MCL were 17.7 and 15.1 months, with notable overall survival rates of 88.5% for CLL/SLL and 65.8% for MCL after 12 months.
  • * Adverse events were common, with significant rates of infections (53.5% for CLL/SLL) and bleeding (5.
View Article and Find Full Text PDF
Article Synopsis
  • Rituximab maintenance is a treatment for young patients with a kind of cancer called mantle cell lymphoma after they receive stem cell transplants.
  • A study compared the number of infections and immune system effects in patients who got rituximab versus those who only monitored their health after the transplant.
  • Results showed that while both groups had similar issues in the first year, those on rituximab had more fevers and infections later, but having low immunoglobulin levels (a type of antibody) helped some patients live longer without cancer returning.
View Article and Find Full Text PDF

Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS).

View Article and Find Full Text PDF

Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses in patients with CLL after the first, second, and third doses of the BNT162b2 or mRNA-1273 vaccines and after a single dose for patients with confirmed previous COVID-19. In all, 530 patients were included in the study.

View Article and Find Full Text PDF

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.

View Article and Find Full Text PDF
Article Synopsis
  • Dasatinib, a medication for chronic myeloid leukaemia (CML), was studied for its potential to cause pleural effusion (fluid buildup in the lungs) in patients taking it.
  • A clinical trial was conducted with patients taking 100 mg of dasatinib, assessing whether therapeutic drug monitoring (TDM) could reduce significant side effects by comparing a dose-reduction strategy with standard care.
  • Although the main goal of reducing adverse events wasn't achieved due to early complications, TDM significantly lowered the incidence of pleural effusion in the long run while maintaining similar molecular responses across treatment groups.
View Article and Find Full Text PDF

The BCL2 inhibitor venetoclax is transforming the management of patients with chronic lymphocytic leukemia (CLL), given its high efficacy in relapsed/refractory CLL as observed in both early-phase and randomized clinical trials. The present study aimed to determine whether venetoclax is effective and well tolerated in patients with CLL or Richter's syndrome (RS) in a real-world setting and to highlight factors impacting survival. Data from a venetoclax French compassionate use program were collected for 67 patients (60 with CLL and 7 with RS).

View Article and Find Full Text PDF

Trials assessing first-line, fixed-duration approaches in chronic lymphocytic leukemia (CLL) are yielding promising activity, but few long-term data are available. We report follow-up data from a phase 2 trial (ICLL07 FILO) in previously untreated, medically fit patients (N = 135). Patients underwent obinutuzumab-ibrutinib induction for 9 months; then, following evaluation (N = 130 evaluable), those in complete remission and with bone marrow measurable residual disease (BM MRD) <0.

View Article and Find Full Text PDF

As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.

View Article and Find Full Text PDF

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.

View Article and Find Full Text PDF

The coexistence of dual hematological neoplasms is very rare. Sequential or synchronous neoplasms in hematology are an uncommon and complex clinical situation. The aim of the Hemo study was to describe the clinical characteristics and analyze the outcome of these patients.

View Article and Find Full Text PDF

Background: In patients with chronic lymphocytic leukaemia, achievement of a complete response with minimal residual disease of less than 0·01% (ie, <1 chronic lymphocytic leukaemia cell per 10 000 leukocytes) in bone marrow has been associated with improved progression-free survival. We aimed to explore the activity of induction therapy for 9 months with obinutuzumab and ibrutinib, followed up with a minimal residual disease-driven therapeutic strategy for 6 additional months, in previously untreated patients.

Methods: We did a single-arm, phase 2 trial in 27 university hospitals, general hospitals, and specialist cancer centres in France.

View Article and Find Full Text PDF

We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a maximum of six cycles of treatment at 28-day intervals.

View Article and Find Full Text PDF
Article Synopsis
  • - A phase IIIb study assessed the safety of obinutuzumab, a treatment for chronic lymphocytic leukemia, given alone or combined with various chemotherapy options, involving 972 patients from October 2013 to March 2016.
  • - The study found that 80.3% of patients experienced grade ≥3 adverse events, with neutropenia, thrombocytopenia, and pneumonia being the most common, and infusion-related reactions were reported in 65.4% of patients.
  • - Despite the reported toxicities, overall response rates surpassed 80% for patients receiving obinutuzumab with chemotherapy after three months, suggesting that the treatment is effective and manageable for this patient group.
View Article and Find Full Text PDF